COVID-19 vaccines profits in 2022

It is known that the goal of vaccine developers is to mimic a natural infection as closely as possible without getting a healthy individual sick.

The arrival of Covid-19 vaccines promises a return to more normal life and has created a global market worth tens of billions of dollars in annual sales for some pharmaceutical companies.

Pfizer

- One of the world’s largest pharmaceutical companies, based in New York, in collaboration with German biotech company BioNTech.

- According to the first-quarter results published by Pfizer this week, its coronavirus jab BNT162b2, made in partnership with BioNTech, has reaped revenues of $3.5bn for the biopharma giant in the first three months of 2021.

- Governments have ordered about 780m shots, including the US (200m doses for $3.9bn) and the EU commission (300m), while 40m doses will go to lower-income nations via the Covax facility. It costs $39 (£28) for two doses in the US and about $30 in the EU.

- Expected sales in 2021: $15bn-$30bn

Read more: How Bill Gates spent over $319 million to Shape the Media

Moderna

- A Massachusetts-based biotech company, in collaboration with the National Institutes of Health.

- The vaccine brought Moderna revenue of $1.73 billion in the first quarter, reflecting three full months of its use in the U.S. and initial international sales, the company said Thursday.

- The UK has ordered 17m doses, the EU bought 310m with an option for a further 150m in 2022, while the US government ordered 300m shots. Japan purchased 50m shots. Moderna charges $30 for the required two shots in the US and $36 in the EU.

- Expected sales in 2021: $18bn-$20bn

Johnson & Johnson

- One of the world’s largest multinational corporations, based in New Jersey, specializing in healthcare and pharmaceutical products.

- It was approved in the US in late February and can be stored at standard fridge temperatures for at least three months. Big orders include the US, UK (30m doses plus option for 22m), the EU (up to 400m doses), and Covax nations (500m doses through 2022).

- Expected sales in 2021: up to $10bn

Read more: Comparing vaccines: country of origin, safety, price, efficacy, and approval

AstraZeneca

- The U.K. university, in collaboration with the biopharmaceutical company AstraZeneca.

- AstraZeneca’s Covid vaccine brought in $275 million in 2021 first-quarter revenue

- In an upbeat earnings report today , Anglo-Swedish drugmaker AstraZeneca reported $275 million in revenue from its Covid-19 vaccine in the first three months of the year.

- Big orders have come from the UK (100m), the EU (up to 400m), the US (300m) and Japan (£120m).

- Expected sales in 2021: $2bn-$3bn

                                                         Read All Articles Here